Advanced artificial intelligence (AI) technologies are now widely employed in China’s medical and healthcare fields. Enormous amounts of personal data are collected from various sources and inserted into AI algorithms for medical purposes, producing challenges to patient’s privacy. This is a comparative study of Chinese, United States, and European Union operational rules for healthcare data that is collected and then used in AI functions, particularly focusing on legal differences and deficiencies. The conceptual boundaries of privacy and personal information, the influence of technological development on the informed consent model, and conflicts between freedom and security in rules of cross-border data flow were found to be key issues requiring consideration when regulating healthcare data used for AI purposes. Furthermore, the results indicate that the appropriate balance between privacy protections and technological development, between individual and group interests, and between corporate profits and the public interest should be identified and observed. In terms of specific rule-making, it was found that China should establish special regulations protecting healthcare information, provide clear definitions and classification schemas for different types of healthcare information, and enact stricter accountability mechanisms. Examining and contrasting operational rules for AI in health care promotes informed privacy governance and improved privacy legislation.
The rise of the synthetic opioid epidemic has time and time again brought criticism on China and India, the world’s two main producers of fentanyl and its chemical precursors. In the past few years, the two countries have attempted to strengthen regulations over fentanyl production and distribution, though its effects on global drug governance remain under scrutiny. This study used qualitative and comparative methods to investigate the current regulatory landscape for fentanyl, including its efficiency and potential loopholes in China and India. It concludes that although both China and India are actively and significantly attempting to step away from the global fentanyl supply chain, these efforts remain ineffective due to institutional loopholes, namely inadequate legislation and fragmented regulatory structures. From insights gained on global drug governance, we recommend a binding international convention concentrated on controlling fentanyl and its related substances, with further bilateral and multilateral cooperation among states as necessary complementation.
The tenth anniversary of China’s Health Silk Road (HSR) offers a timely opportunity to review its contributions and challenges in advancing global health governance and international public health cooperation. As important health-related global public goods (GPGs), the HSR has sought to promote equitable access to health resources, reduce disparities among partner countries, and strengthen international collaboration in line with the UN Sustainable Development Goals (SDGs). This policy and practice review critically analyzes the governance structure, policy mechanisms, and implementation experiences of the HSR, using policy documents, international organization reports, and comparative case analysis. The review identifies central challenges, including regulatory fragmentation, inconsistent recognition of medical qualifications, and varying standards for health practices across diverse cultural and political contexts. It emphsizes the need for more transparent, inclusive, and rule-based governance frameworks that generates mutual trust and integration of non-state actors. The paper offers policy recommendations to strengthen cross-border cooperation, promote mutual learning, and deepen international partnerships, aiming to inform the future development of more transparent, inclusive, and rule-based global health governance rooted in diverse regional experiences.
This study examines how Chinese drug regulations are shifting illicit fentanyl production from China to India. This change has implications for the law, drug enforcement, pharmaceutical industry, and public health, as domestic production increases domestic access to fentanyl, in India. An empirical examination of current trends in fentanyl production and use in the region is conducted, along with an exegesis of the legal and regulatory systems in China and India. There is an accounting of the chemical and pharmaceutical industries, the strengths and weaknesses of drug legislation, and the public health consequences of increased production, distribution, and use of fentanyl in India. This study also details how the Indian government meets this challenge through legislative mechanisms, foremost through class-wide legislative control over fentanyl and its precursors. Class-wide control prohibits the unlawful production and distribution of all current and future fentanyl analogs and their precursors, disincentivizing and disrupting their development and production. The Indian government should also reduce domestic demand by promoting harm reduction measures such as opioid substitution therapy, evidence-based treatment, fentanyl test strip and naloxone distribution, and needle exchange programs.
Background/Objectives: The COVID-19 pandemic compelled countries worldwide to implement stringent visitation restrictions across hospitals, nursing homes, and long-term care facilities to mitigate viral transmission. While initially justified by the uncertainty surrounding the virus, these restrictions often lasted well beyond the acute stage of the pandemic, leading to substantial psychological and physical harm, particularly for older adults. This study assesses the effects of these controls and offers strategies to balance public health priorities with patients’ rights and psychological well-being during public health crises. Methods: An integrative review and comparative analysis of legislative measures and the psychological effects of visitation restrictions was undertaken. International and national visitation regulations and case studies were reviewed, and ethical frameworks were considered. Results: Our findings indicate that prolonged isolation due to extended visitation restrictions led to higher rates of anxiety, depression, and delirium among patients, creating ethical dilemmas for healthcare providers. Legal responses to this challenge varied globally. International human rights organizations called for policies bridging public health priorities with patients’ rights to family and caregiver support. Some U.S. states enacted proactive legislation to strengthen family visitation rights, while other jurisdictions lack these visitation protections. Conclusions: Prolonged visitation restrictions during the pandemic show the need for legislation integrating public health protections with in-person family and caregiver support. The ethical imperatives of limiting the psychological harm caused by healthcare isolation and the legislative solutions to protect public health and the psychological well-being of patients during health crises are discussed.